Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study - Top-Institutions - MDSpire

Infection Risk Assessment of Ocrelizumab Versus Rituximab in Multiple Sclerosis: Findings from a Nationwide Cohort Study in Sweden

  • By

  • Thomas Frisell

  • Sebastian Hedberg

  • Fredrik Piehl

  • June 17, 2026

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Swedish MS Registry
    Swedish MS Registry

    Uppsala, Uppsala County

    Key Differentiators

    • Neurology

  • #2

    Swedish Ethical Review Authority
    Swedish Ethical Review Authority

    Stockholm, Stockholm County

    Key Differentiators

    • Ethics

  • #3

    University Hospital Policlinico of Bari
    University Hospital Policlinico of Bari

    Bari, Apulia

    Key Differentiators

    • Neurology

Original Source(s)

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study

  • by Thomas Frisell, Sebastian Hedberg, Fredrik Piehl

  • June 17, 2026

Related Content

Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes

Mechanisms and therapeutic advances of gut metabolites in the regulation of neuroimmune inflammatory diseases

HLA-DRB1*15:01 drives sex- and age-dependent microglial immune phenotypes and neuroimmune signaling